Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Philipp Berning,Maud Ngoya,Norbert Schmitz,Herve Finel,Ariane Boumendil,Won-Seog Kim,Fengrong Wang,Xiao-jun Huang,Olivier Hermine,Laure Philippe,Lucile Couronne,Arnaud Jaccard,Daihong Liu,Depei Wu,Hans Christian Reinhardt,Yves Chalandon,Eva Maria Wagner,Mi Kwon,Xi Zhang,Ben Carpenter,Ibrahim Yakoub-Agha,Gerald Wulf,Javier Lopez Jimenez,Jaime Sanz,Helene Labussiere-Wallet,Avichai Shimoni,Peter Dreger,Anna Sureda,Bertram Glass
DOI: https://doi.org/10.1182/blood-2022-164637
IF: 20.3
2022-01-01
Blood
Abstract:Introduction Extranodal NK/T-cell lymphomas (ENKTL) represent aggressive lymphoid malignancies predominantly occurring in Asia and South America being rare in the Western world. Stage I/II patients are treated with asparaginase-containing (ASP) chemotherapy and local radiotherapy. For advanced stages III/IV and patients (pts) with relapsed/refractory disease current guidelines recommend ASP-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). These recommendations, however, are mostly based on small series of patients (<20 pts) partly reported decades ago. The largest series reported by CIBMTR comprised 82 pts, most of them still having been treated with anthracycline-containing regimens before HSCT (Kanate AS Br J Haematol 2018,182, 909). Methods We conducted a retrospective analysis of EBMT registry data and data from registries of cooperating Asian centers in China and South Korea. The following inclusion criteria were applied: pts with confirmed ENKTL, age ≥18 years, first HSCT between 2013 and 2020, previous autologous stem cell transplantation allowed. Outcome data were calculated from the day of HSCT until the respective event. Results In total, 137 pts were identified with a median age of 43.4 years (95% CI: 18.3 - 67.7 years) at the time of HSCT; 68.6% were male. Median follow-up was 4.8 years (95% CI: 3.7 - 5.9 years). Recipients were predominantly European (99 pts), 38 pts were of Asian ethnicity. High PINK scores at diagnosis were reported for 67.8%; 32.2% had low/intermediate PINK scores. Two or more treatment lines had been applied in 79.5% of cases prior to HSCT. Importantly, 73.5% of our pts had received ASP-containing regimens prior to HSCT. Autologous transplantation prior to HSCT had been performed in 21.9% of cases. Remission status at the time of HSCT was complete remission (CR) in 53.7%, partial remission (PR) in 26.5%, and chemorefractory/progressive disease in 12.5%. Reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) were used in 46.7% and 53.3% of cases, respectively. The 1-year and 3-year progression-free survival (PFS) rate for all pts on the study was 55.5% (95% CI: 46.6 - 63.6%) and 48.6% (95% CI: 39.7 - 57%), respectively. The corresponding overall survival (OS) rates were 66.6% (95% CI: 58 - 73.9%) and 55.6% (95% CI: 46.5 - 63.7%), respectively. The cumulative incidence of non-relapse mortality (NRM) at 1 year and 3 years was 15.3% (95% CI: 9.7 - 22.1%) and 17.8% (95% CI: 11.8 - 24.9%) with a relapse incidence (RI) of 29.1% (95% CI: 21.6 - 37.1%) and 33.5% (95% CI: 25.4 - 41.8%) at 1 year and 3 years, respectively. Of note, no relapse was noted beyond 3 years after HSCT. In univariate analyses, ethnicity (European vs. Asian) did not significantly influence PFS (p=0.57), OS (p=0.57), NRM (p=0.79) or RI (p=0.65). Among patients receiving RIC vs. MAC regimens, the relapse incidence (p=0.29) and NRM (p=0.20) were not significantly different. For haploidentical (n=27 pts) vs. HLA-matched related and unrelated donors, no significant differences in terms of PFS (39% (95% CI: 20.2 - 57.4%) vs. 51% (95% CI: 40.9 - 60.2%)), OS (52.6% (95% CI: 31.5 - 70%) vs. 56.1% (95% CI: 46 - 65.1%)), NRM (20.3 (95% CI: 7.1 - 38.3%) vs. 17.3% (95% CI: 10.7 - 25.2%)) and RI (40.7% (95% CI: 21 - 59.6%) vs. 31.7% (95% CI: 22.9 - 40.8%)) at 3 years were observed. For the group of ASP-pretreated patients, 3 year PFS, OS, RI and NRM were 42.4% (95% CI: 32.1 - 52.2%), 52.2% (95% CI: 41.5 - 61.8%), 39.6% (29.5 - 49.5%) and 18.1% (95% CI: 11 - 26.6%), respectively. PD-1 treatment prior to HSCT was applied in 13 patients; these pts did not show significant differences in PFS or OS as compared to all other pts. We also did not observe an increased risk for NRM or acute/chronic GvHD in these pts. Conclusions In a large cohort of Asian and European pts, we demonstrate that HSCT is an effective treatment approach for advanced ENKTL with almost half of the pts achieving long-term survival. These results obtained with the majority of pts having been treated with state-of-the-art ASP-containing therapy prior to transplant compare favorably to previous analyses and show that HSCT is the preferred option for younger pts with ENKTL. PD-1 antibodies given prior to HSCT may help to bring more pts to HSCT without negatively influencing treatment outcomes or GvHD.